Brentuximab
Brentuximab
Brentuximab (pronounced: brent-ux-i-mab) is a type of antibody-drug conjugate used in the treatment of certain types of cancer. It is specifically used for Hodgkin's lymphoma and systemic anaplastic large cell lymphoma that has not improved following other treatments.
Etymology
The name "Brentuximab" is derived from the combination of "brent", a term of unknown origin, and "uximab", a common suffix for monoclonal antibodies. The "uxi" part of the suffix indicates that the drug targets a cancer cell, and the "mab" part indicates that it is a monoclonal antibody.
Usage
Brentuximab is used to treat Hodgkin's lymphoma and systemic anaplastic large cell lymphoma that has not improved following other treatments. It works by binding to a protein on the surface of cancer cells, which allows it to deliver a toxic substance directly to the cells, causing them to die.
Related Terms
- Antibody-drug conjugate: A type of drug that combines an antibody with a chemotherapy drug. The antibody is designed to target a specific protein on the surface of cancer cells, allowing the chemotherapy drug to be delivered directly to the cells.
- Hodgkin's lymphoma: A type of cancer that starts in white blood cells called lymphocytes.
- Anaplastic large cell lymphoma: A type of non-Hodgkin lymphoma that primarily affects the skin, but can also involve lymph nodes, lungs, liver, and other organs.
- Monoclonal antibody: A type of protein made in the lab that can bind to substances in the body, including cancer cells.
External links
- Medical encyclopedia article on Brentuximab
- Wikipedia's article - Brentuximab
This WikiMD article is a stub. You can help make it a full article.
Languages: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
Urdu,
বাংলা,
తెలుగు,
தமிழ்,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
European
español,
Deutsch,
français,
русский,
português do Brasil,
Italian,
polski